The use of danaparoid to manage coagulopathy in a neurosurgical patient with heparin-induced thrombocytopenia type II and intracerebral haemorrhage.

Abstract

This study presents a case of bifrontal intracerebral haemorrhage in a patient with heparin-induced thrombocytopenia type II (HIT II). HIT II was induced by treatment with low-molecular-weight heparin for recurrent deep vein thrombosis caused by essential thrombocytosis and accompanied by hepatic thromboembolism. This patient was treated with platelet substitution and neurosurgical haematoma evacuation. Anticoagulation with 2500 units danaparoid per day was sufficient for therapy of thrombosis and no rebleeding occurred.

• Authors: Daniel N Hertle, Stefan Hähnel, Götz M Richter, Andreas Unterberg, Oliver W Sakowitz, Karl L Kiening
• Journal: British journal of neurosurgery (Br J Neurosurg) Vol. 25 Issue 1 Pg. 117-9 (Feb 2011) ISSN: 1360-046X [Electronic] England
• PMID: 20707682 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anticoagulants
• Heparin, Low-Molecular-Weight
• Dermatan Sulfate
• Chondroitin Sulfates
• Heparitin Sulfate
• danaparoid

Topics

• Aged
• Anticoagulants (administration & dosage, adverse effects)
• Blood Coagulation Disorders (drug therapy)
• Cerebral Hemorrhage (chemically induced, drug therapy)
• Chondroitin Sulfates (administration & dosage)
• Chromosome Breakage
• Chromosome Disorders (chemically induced, drug therapy)
• Dermatan Sulfate (administration & dosage)
• Heparin, Low-Molecular-Weight (adverse effects)
• Heparitin Sulfate (administration & dosage)
• Humans
• Male
• Thrombocytopenia (chemically induced, congenital, drug therapy)
• Treatment Outcome